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Abstract Peptide nucleic acids (PNAs) are DNA mimics with 
a peptide backbone. PNAs are being intensely investigated owing 
to a potential as gene-targeted drugs. A PNA (H-GTAGAT- 
CACT-NH&DNA (S-AGTGATCTAC-3’) complex has been 
crystallized in a tetragonal space group P4,22 with cell dime?- 
sions a = b = 79.8, c = 99.9 A. The crystals diffract to about 5 A 
resolution. 
[13,14]. However, a high resolution molecular structure is not 
yet available and would be indispensable for further rational 
design of new DNA mimics and for a molecular understanding 
of the DNA binding properties of PNA. 
We now report the crystallization of a PNA-DNA complex 
as a first step towards this goal. 
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2. Materials and methods 
1. Introduction 
PNA (peptide nucleic acid) is a recently developed oligonu- 
cleotide analogue in which the entire backbone has been re- 
placed by a pseudopeptide backbone composed of N-(2-ami- 
noethyl)glycine units [l-3]. Although the new backbone chem- 
ically does not even remotely resemble the deoxyribose 
phosphodiester backbone of DNA, it is structurally homomor- 
phous to this. Experiments revealed that PNA is close to a 
perfect structural mimic of DNA in terms of its ability to form 
double helical complexes with complementary oligonucleotides 
[4] and complementary PNAs [S], and the complex formation 
obeys the Watson-Crick base pairing rules (adenine-thymine, 
and guanine-cytosine recognition) (Fig. 1). 
The PNA H-GTAGATCACT-NH, (I) was synthesized as described 
[2] and purified by HPLC. The complementary, antiparallel oligonucle- 
otide 5’-AGTGATCTAC-3’ (II) was synthesized by the standard 
phosphoramidite procedure. The ratio of PNA to oligonucleotide to be 
used for crystallization experiments was determined experimentally by 
titration using a gel shift assay and a trace amount of ‘*P-labeled 
oligonucleotide. The oligonucleotide was labeled with ‘*P at the 5’-end 
using [y3*P]ATP (5000 Ci/mmol; Amersham) and T, polynucleotide 
kinase 1151. 
PNA (I) and DNA (II) were mixed in an approximately 1: 1 ratio, 
yielding a concentration of 3.5 me/ml for the PNA-DNA comolex in 
PNA can also bind to double-stranded DNA by strand dis- 
placement [ 1,6]. Two PNA strands are bound to the one DNA 
strand, by Watson-Crick or Hoogsteen base pairing [7]. 
water. Crystals were obtained by the hanging drop vapor diffusion 
method [16]. 3-5 ,ul of PNA-DNA were mixed on a siliconized coverslip 
with equal volumes of well solution, typically 14% PEG 6000,200-300 
mM zinc acetate and 100 mM sodium cacodylate buffer, pH 6.5, and 
equilibrated at room temperature over 0.5 ml of well solution using a 
Lindbro tissue culture plate (Flow Lab Inc.; McLean, VA, USA). 
Within 4 days crystals grow to a size of 0.2 x 0.2 x 0.2 mm. By repeated 
seeding experiments crystal size was improved to 0.5 x 0.5 x 0.5 mm 
within an additional 4 days. The crystal was moved into a new drop 
containing 2 mg/ml PNA-DNA, 5% PEG 6000, 130 mM zinc acetate, 
and 40 mM cacodylate buffer, pH 6.5, and equilibrated over 0.5 ml of 
well solution containing 12% PEG 6000, 300 mM zinc acetate, and 100 
mM sodium cacodylate buffer, pH 6.5. 
Upon binding to mRNA, PNA interferes with ribosome 
function and thus acts as an antisense inhibitor of translation 
[8]. PNA bound at a protein (restriction enzyme) recognition 
site efficiently inhibits the cleavage at this site by the enzyme 
[9]. When a PNA binding site is positioned downstream from 
a promoter, transcription elongation by RNA polymerase is 
affected when PNA is bound to the template strand, but is only 
little affected when PNA is bound to the non-template strand 
[&lo]. Thus, PNA has many of the properties desired of an 
antisense/antigene drug candidate [S, 111, including stability to- 
wards nucleases, proteases, peptidases and human serum [12]. 
A full X-ray data set was collected on one crystal to 5 8, resolution 
on an R-AXIS II imaging plate detector system using a Rigaku RU200 
rotating anode generator (a= 1.542 A, 50 kV, 180 mA). Data were 
processed using the program DENZO [17] and the CCP4 suite of 
programs [18] and visualized with the program PRECESS [19]. 
3. Results and discussion 
3.1. Crystallization of the PNA (I)-DNA (II) complex 
Circular dichroism results have shown that PNA-DNA com- 
plexes adopt a B-like helical structure while PNA-RNA com- 
plexes resemble more the A-form [4]. These conclusions were 
recently confirmed by two-dimensional NMR spectroscopy 
*Corresponding authors. Fax: (45) 35 37 22 09. 
Bipyrimidal crystals of PNA-DNA were obtained by the 
hanging drop method using PEG as precipitant and zinc acetate 
as additive (Fig. 2). The addition of zinc acetate was essential 
to crystal growth, and substitution with other divalent cations 
(magnesium, calcium, cobalt, and copper) did not result in any 
regular crystals. In addition, the acetate anion was clearly to 
be preferred over chloride and sulphate as anions. Zinc ions 
have not been used for crystallization of any DNA-DNA or 
DNA-RNA complexes deposited in the Biological Macromol- 
ecule Crystallization Database [20]. 
Abbreviations: PNA, peptide nucleic acid; PEG, polyethylene glycol. Crystals were grown to a maximum size of 0.2 x 0.2 x 0.2 mm 
0014-5793/95/$9.50 0 1995 Federation of European Biochemical Societies. All rights reserved 
SSDI 0014-5793(95)00294-4 
116 J.S. Kustrup et al.IFEBS Letters 363 (1995) 115-117 
5 
DNA 
3 
0, PH 
O)P 
0’ ’ 4 
9x 
i 
L 0 BaSe 
0, P 
0)P 
0’ ’ 
“\ 
0 b Base 
HO 
Base 
-J- 
0 
‘NH 
04 
PNA 
Fig. 1. Schematic representation of a PNA-DNA complex. The repeat- 
ing PNA and DNA units are marked by brackets. 
within 4 days at room temperature. These crystals show diffrac- 
tion to about 13 A resolution. After repeated seeding crystal 
size was increased to 0.5 x 0.5 x 0.5 mm; hereby the diffraction 
was improved to 5 A resolution. Within this resolution shell the 
diffraction is very strong, while outside this shell the crystals 
show no diffraction at all (Fig. 3). The crystals are stable for 
at least 4 days in the beam showing no decrease in diffraction. 
A complete (98.8%) data set was collected to 5.0 A resolution 
(R,,, = 12.1%, I/o(I) = 3.8). PNA-DNA crystallizes in the te- 
tragonal space group P4,22 with cell dimensions of 
u = h = 79.8, c = 99.9 A. Estimating the solvent content as for 
Fig. 2. Crystals of the PNA-DNA complex (bar indicates 0.1 mm). 
protein crystals [21], the crystals of PNA-DNA contain 64% 
solvent for 32 PNA-DNA complexes in the unit cell, 46% for 
48, and 28% for 64. Comparing the volume occupied by differ- 
ent DNA-DNA decamers from structures deposited in the 
Protein Data Bank, January release 1995 [22], an average vol- 
ume of 13.460 A’ per DNA-DNA complex is found, ranging 
from 10.070 A’ to 17.492 A’. The decamer structures deposited 
crystallize in either a monoclinic, orthorhombic or hexagonal 
space group. The average volume indicates 48 complexes of 
Fig. 3. Diffraction pattern obtained from a PNA-DNA crystal on an R-AXIS II imaging plate detector system using a Rigaku RU200 rotating anode 
generator (I = 1.542 A, 50 kV, 180 mA). The picture shows a 2” oscillation, crystal-imaging plate distance 90.0 mm. 
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Fig. 4. Detection of oligonucleotide (II) and PNA (I) in crystals. Lane 
1, 5’ 32P-end labeled oligonucleotide (II); lane 2, sample as in lane 1 
except that 1 fig of PNA (I) was included; lane 3, sample as in lane 1 
except that crystal material corresponding to appr. 0.1 pug was added; 
lane 4, crystal material (appr. 0.1 pug) treated with [y’*P]ATP and pol- 
ynucleotide kinase. The samples were analyzed by electrophoresis in a 
15% polyacrylamide gel run in TBE buffer (90 mM Tris-borate, 1 mM 
EDTA, pH 8.3). The bands containing “P-labeled oligonucleotide were 
visualized by autoradiography using intensifying screens. 
PNA-DNA per unit cell. However, the large range in observed 
volume might suggest numbers of 32 to 64 complexes. 
3.2. Biochemical characterization of the crystals 
Isolated and washed crystals were analyzed for their content 
of PNA (I) and oligonucleotide (II) by polyacrylamide gel elec- 
trophoresis. 
In one experiment it was shown that the crystals contain 
material that is able to bind to “P-labeled oligonucleotide (II) 
and produce a gel-retarded complex that has the same migra- 
tion as that produced by an authentic sample of the comple- 
mentary PNA (I) (Fig. 4, lanes 2 and 3). 
In another experiment crystal material was treated with 
[Y~~P]ATP and polynucleotide kinase, and upon gel analysis a 
major 3’P-labeled component migrating as “2P-labeled oligonu- 
cleotide (II), as well as a minor component migrating as the 
authentic PNA-oligonucleotide complex, were observed. 
We therefore conclude that the crystals contain both PNA 
(I) and oligonucleotide (II). 
3.3. Work in progress 
So far crystals of the PNA (I)-DNA (II) complex have been 
obtained diffracting to 5 A resolution. The experimental condi- 
tions for crystallization of PNA-DNA and for data collection 
are being optimized in order to obtain higher resolution. 
117 
Work is in progress to solve the 5 A structure of the PNA- 
DNA complex by molecular replacement techniques. A model 
of a PNA (I)-DNA (II) complex and of an analogous DNA- 
DNA complex have been constructed by molecular modelling 
(to be published). These models are being used as search models 
for molecular replacement. 
Acknowiedgenwnts: This work was supported by The PharmaBiotec 
Research Center, The Lundbeck Foundation, The Danish Medical and 
Technical Research Councils, and The Danish Basic Research Founda- 
tion 
References 
[II 
PI 
[31 
[41 
[51 
PI 
[71 
PI 
191 
[lOI 
u11 
WI 
[I31 
[I41 
u51 
iI61 
u71 
[I81 
iI91 
PO1 
PII 
m 
Nielsen, P.E., Egholm, M., Berg, R.H. and Buchardt, 0. (1991) 
Science 254, 1497-1500. 
Dueholm, K.L., Egholm, M., Behrens, C., Christensen, L., 
Hansen, H.F., Vulpius, T., Petersen, K., Berg, R.H., Nielsen, P.E. 
and Buchardt, 0. (1994) J. Org. Chem. 59, 576775773. 
Nielsen, P.E., Egholm, M. and Buchardt, 0. (1994) Bioconjugate 
Chem. 5, 3-7. 
Egholm, M., Buchardt, O., Christensen, L., Behrens, C., Freier, 
S.-M., Driver, D.A., Berg, R.H., Kim, S.K., Norden, B. and 
Nielsen. P.E. (1993) Nature 365. 556-568. 
Wittung, P., Nielsen, P.E., Buchardt, O., Egholm, M. and Norden, 
B. (1994) Nature 368, 561-563. 
Cherny, D.Y., Belotserkovskii, B.P., Frank-Kamenetskii, M.D., 
Egholm, M., Buchardt, O., Berg, R.H. and Nielsen, P.E. (1993) 
Proc. Natl. Acad. Sci. USA 90, 166771670. 
Nielsen, P.E., Egholm, M. and Buchardt, 0. (1994) J. Mol. Recog- 
nition 7. 1655170. 
Hanvey. J.C., Peffer, N.C., Bisi, J.E., Thomson, S.A., Cadilla, R., 
Josey. J.A., Ricca, D.J., Hassman, C.F., Bonham, M.A., Au, 
K.G., Carter, S.G., Bruckenstein, D.A., Boyd, A.L., Noble, S.A. 
and Babbis, L.E. (1992) Science 258, 1481-1485. 
Nielsen, P.E., Egholm, M., Berg, R.H. and Buchardt, 0. (1993) 
Nucleic Acids Res. 21, 1977200. 
Nielsen, P.E., Egholm, M. and Buchardt, 0. (1994) Gene 149, 
139-145. 
Nielsen, P.E., Egholm, M., Berg, R.H. and Buchardt, 0. (1993) 
Anti Cancer Drug Design 8, 53363. 
Demidov, V., Potaman, V.N., Frank-Kamenetskii, M.D., 
Buchardt, O., Egholm, M. and Nielsen, P.E. (1994) Biochem. 
Pharmacol. 48, 130991313. 
Leijon, M., Graslund, A., Nielsen, P.E., Buchardt, O., Norden, B., 
Kristensen, S.M. and Ericsson, M. (1994) Biochemistry 33, 9820- 
9825. 
Brown, S.C., Thomson, S.A., Veal, J.M., Davis, D.G. (1994) Sci- 
ence 265, 7777780. 
Sambrook, J., Fritsch, E. and Maniatis, T. (1989) in: Molecular 
Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor, New York. 
McPherson, A.J. (1982) in: Preparation and Analysis of Protein 
Crystals, pp. 822160, Wiley, New York. 
Otwinowski, Z. (1986) DENZO Program: An Oscillation Data 
Processing Program for Macromolecular Crystallography, Yale 
University, CT, USA. 
Collaborative Computational Project, Number 4 (1994) Acta 
Cryst. D50, 760-763. 
Furey, W. (1991) PRECESS Program, University of Pittsburg, 
PA, USA. 
Gilliland, G.L., Tung, M., Blakeslee, D.M., and Ladner, J. (1994) 
Acta Crystallogr. D50, 408413. 
Matthews, B.W. (1968) J. Mol. Biol. 33, 491497. 
Bernstein, F.C., Koetrle, T.F., Williams, G.J.B., Meyer Jr., E.F., 
Brice, M.D., Rogers, J.R., Kennard, O., Shimanouchi, T, and 
Tasumi, M. (1977) J. Mol. Biol. 112, 535-542. 
